Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells

Standard treatment for primary prostate cancer includes systemic exposure to chemotherapeutic drugs that target androgen receptor or antihormone therapy (chemical castration); however, drug-resistant cancer cells generally emerge during treatment, limiting the continued use of systemic chemotherapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yayun, Mafuvadze, Benford, Aebi, Johannes D, Hyder, Salman M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892832/
https://www.ncbi.nlm.nih.gov/pubmed/27313468
http://dx.doi.org/10.2147/OTT.S105725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892832/
https://www.ncbi.nlm.nih.gov/pubmed/27313468
http://dx.doi.org/10.2147/OTT.S105725

Ejemplares similares